Good morning, and welcome to the 2026 Annual Meeting of Tango Therapeutics. We are very pleased to have you with us. I am Dr. Barbara Weber, Executive Chair of Tango Therapeutics. We're pleased to be hosting our virtual meeting, which allows us to be more inclusive and reach a greater number of our stockholders. All stockholders participating in the meeting are attending via the web portal. We will conduct the business portion of our meeting first and answer questions after the presentation of the proposals. It is now shortly after 9:00 A.M. Eastern Time on June 4th, 2026, and this meeting is officially called to order. The business before this meeting is described in our notice of annual meeting of stockholders and proxy statement, a copy of which has been provided to our stockholders. The rules of conduct will govern how we run the meeting. They are available with the other meeting materials on the link on the web portal. I will now turn the meeting over to Dr. Malte Peters, the Chief Executive Officer of Tango Therapeutics. Dr. Peters will preside over today's meeting. Thank you, Barbara. I also want to extend my welcome to those shareholders who are able to join us for this annual meeting. Before proceeding to the formal business, I would like to introduce the members of our board and management who are with us today. Our outside directors are Lesley Ann Calhoun, Sung Lee, and Dr. Mace Rothenberg. Our members of management here today are Matt Gall, Chief Financial Officer, Adam Crystal, President, Research and Development, and Julie Fogarty, Vice President, Legal and Corporate Secretary. Broadridge Financial Solutions has acted as the tabulator for this annual meeting and has delivered to Julie Fogarty, Vice President, Legal and Corporate Secretary, a final vote tabulation report as of 12:00 A.M. this morning, signed by an authorized representative of Broadridge. Peder Hagberg of Broadridge will act as the Independent Inspector of Elections. He has taken his oath as the Inspector of Elections, which will be filed with the company's records. Frank Loftus of PricewaterhouseCoopers, our independent registered public accounting firm, is with us this morning. He's available to answer questions raised at this meeting as appropriate. After a review of the proposals, we will provide time for questions. Only validated stockholders may ask questions in the designated field on the web portal. Out of consideration for others, please limit yourself to one question. Please note that this meeting is being recorded. No one attending via the web portal is permitted to use any audio recording device. The Board of Directors chose the close of business on April 7th, 2026, as the record date for determining stockholders entitled to vote at this meeting. An affidavit has been delivered to the board attesting to the fact that the 2026 annual report on Form 10-K and the Proxy Statement were mailed on or about April 17th, 2026 to all stockholders as of the record date and will be incorporated into the minutes of this meeting. At this meeting, we are asking stockholders to first elect the Class II directors. The board had nominated the Class II directors, Dr. Peters, Dr. Rothenberg, and Kanishka Pothula, to hold office until the 2029 annual meeting of stockholders. However, Mr. Pothula has since resigned from the board, any votes received for Mr. Pothula will be disregarded. Second, ratify the appointment of PricewaterhouseCoopers as our independent registered public accounting firm for the fiscal year ending December 31st, 2026. Third, approve on a non-binding advisory basis the compensation of our named executive officers. In order to begin, our amended and restated bylaws require that the majority of the outstanding shares of our capital stock enlisted to vote be represented in person or by proxy at the meeting for us to have a quorum. The stockholder list shows that as of the record date, there were 144,242,271 shares of common stock outstanding and entitled to vote at this meeting. We are informed by the Inspector of Elections that more than a majority of the shares of common stock on the record date are participating in the meeting, either on behalf of themselves or by proxy. Since this represents more than the majority of the voting power of all issued and outstanding stock entitled to vote on the record date, a quorum is present for purposes of transacting business. This meeting is now duly convened. The report of a quorum and all proxies received at this meeting will be filed in the company's records. We will now consider the proposals. Proposal 1, election of Class II directors. The first proposal is the election of Class II directors, Dr. Peters and Dr. Rothenberg, to our board of directors, each to serve until the 2029 annual meeting of stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation, or removal. If you would like to ask questions pertaining to this proposal, please complete the designated fields on the web portal. Proposal 2, ratification of the appointment of PricewaterhouseCoopers. The second proposal before us today is the ratification of the appointment of PricewaterhouseCoopers as our independent registered public accounting firm for the fiscal year ending December 31, 2026. If you would like to ask a question pertaining to this proposal, please complete the designated fields on the web portal. Proposal 3, advisory vote on compensation of our named executive officers. The third proposal before us today is the approval on a non-binding advisory basis of the compensation of our named executive officers. We will now open the floor to questions concerning the matters to be voted upon. If you would like to ask a question, please enter it into the web portal. Please note that any statements that we make today that are other than historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please be aware that all such forward-looking statements involve risks and uncertainties, such as those detailed in our SEC filings, including our most recent 10-K and 10-Q. Any forward-looking statements that we make must be considered in light of these factors. Actual results may vary materially. Will Mrs. Fogarty please advise if we have any questions? We have no questions appropriately related to the purpose of the meeting. Thank you. As there are no questions, we will proceed to voting. It is now 9:08 A.M. Eastern Time on June 4, 2026. The polls are now open. Any stockholder who hasn't yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and following the instructions there. Stockholders who have sent in proxies or voted via telephone or internet and do not want to change their votes do not need to take any further action, as your shares will be voted accordingly. Now that everyone has had the opportunity to vote, I declare the polls now closed for the 2026 Tango Therapeutics Annual Stockholder Meeting at 9:08 A.M. Eastern Time on June 4th, 2026. The Inspector of Elections has the completed ballots and will certify the voting results. The Inspector of Elections has the preliminary results as of close of voting yesterday. Based on these results, Dr. Peters and Dr. Rothenberg have been elected as directors of the company with terms ending at the annual meetings of stockholders in 2029. In addition, the audit committee appointment of PricewaterhouseCoopers as the company's independent registered public accounting firm for 2026 has been ratified. Finally, the stockholders have approved, on a non-binding advisory basis, the compensation of our named executive officers. Upon certification, a Form 8-K with the final results of the voting will be filed with the SEC within four business days of this meeting. I direct that the report and certificate of the Inspector of Election be filed with the minutes of this meeting. Thank you. This ends the formal portion of our meeting. There being no other business to properly come before this meeting, this meeting is now adjourned. I would like to express my appreciation to the stockholders who attended the meeting and voted, as well as those who submitted their proxies but were not able to be present in person. The 2026 annual meeting of stockholders of Tango Therapeutics is now officially adjourned. This concludes today's conference call. Thank you for your participation. You may now disconnect.